These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 29724204)

  • 1. Efficacy and safety of PDE5-Is and α-1 blockers for treating lower ureteric stones or LUTS: a meta-analysis of RCTs.
    Sun X; Guan W; Liu H; Tang K; Yan L; Zhang Y; Zeng J; Chen Z; Xu H; Ye Z
    BMC Urol; 2018 May; 18(1):30. PubMed ID: 29724204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy of PDE5 inhibitors alone or in combination with alpha-blockers for the treatment of erectile dysfunction and lower urinary tract symptoms due to benign prostatic hyperplasia: a systematic review and meta-analysis.
    Yan H; Zong H; Cui Y; Li N; Zhang Y
    J Sex Med; 2014 Jun; 11(6):1539-45. PubMed ID: 24621088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.
    Gacci M; Corona G; Salvi M; Vignozzi L; McVary KT; Kaplan SA; Roehrborn CG; Serni S; Mirone V; Carini M; Maggi M
    Eur Urol; 2012 May; 61(5):994-1003. PubMed ID: 22405510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparative randomized prospective study to evaluate efficacy and safety of combination of tamsulosin and tadalafil vs. tamsulosin or tadalafil alone in patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
    Singh DV; Mete UK; Mandal AK; Singh SK
    J Sex Med; 2014 Jan; 11(1):187-96. PubMed ID: 24165272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of a Fixed-Dose Combination Therapy of Tamsulosin and Tadalafil for Patients With Lower Urinary Tract Symptoms and Erectile Dysfunction: Results of a Randomized, Double-Blinded, Active-Controlled Trial.
    Kim SW; Park NC; Lee SW; Yang DY; Park JK; Moon DG; Yang SK; Lee SW; Moon KH; Ahn TY; Kim SW; Park K; Min KS; Ryu JK; Son H; Jung J; Hyun JS
    J Sex Med; 2017 Aug; 14(8):1018-1027. PubMed ID: 28760246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic review and meta-analysis on phosphodiesterase 5 inhibitors and α-adrenoceptor antagonists used alone or combined for treatment of LUTS due to BPH.
    Wang XH; Wang X; Shi MJ; Li S; Liu T; Zhang XH
    Asian J Androl; 2015; 17(6):1022-32. PubMed ID: 25994648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alpha-blockers with or without phosphodiesterase type 5 inhibitor for treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review and meta-analysis.
    Zhang J; Li X; Yang B; Wu C; Fan Y; Li H
    World J Urol; 2019 Jan; 37(1):143-153. PubMed ID: 29948047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meta-analysis of the efficacy and safety of combination of tamsulosin plus dutasteride compared with tamsulosin monotherapy in treating benign prostatic hyperplasia.
    Zhou Z; Cui Y; Wu J; Ding R; Cai T; Gao Z
    BMC Urol; 2019 Mar; 19(1):17. PubMed ID: 30871552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, placebo-controlled study to assess safety and efficacy of vardenafil 10 mg and tamsulosin 0.4 mg vs. tamsulosin 0.4 mg alone in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.
    Gacci M; Vittori G; Tosi N; Siena G; Rossetti MA; Lapini A; Vignozzi L; Serni S; Maggi M; Carini M
    J Sex Med; 2012 Jun; 9(6):1624-33. PubMed ID: 22510238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. To evaluate the efficacy and safety of different kinds of PDE5-Is with tamsulosin as a medical therapy for LUTS secondary to benign prostatic hyperplasia: A protocol for systematic review and meta analysis.
    Ma C; Zhang J; Cai Z; Li H
    Medicine (Baltimore); 2020 Jan; 99(3):e18712. PubMed ID: 32011446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination Therapy with Alpha-blocker and Phosphodiesterase-5 Inhibitor for Improving Lower Urinary Tract Symptoms and Erectile Dysfunction in Comparison with Monotherapy: A Systematic Review and Meta-analysis.
    Kallidonis P; Adamou C; Kotsiris D; Ntasiotis P; Verze P; Athanasopoulos A;
    Eur Urol Focus; 2020 May; 6(3):537-558. PubMed ID: 31133414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerability of combination therapy with alpha-blockers and phosphodiesterase-5 inhibitors compared with monotherapy for lower urinary tract symptoms: Protocol for a systematic review and network meta-analysis.
    Qiangzhao L; Xiaofeng Z; Fenghai Z; Qiong L; Fa Z; Bohong G; Xinsheng X
    Medicine (Baltimore); 2020 Oct; 99(43):e22834. PubMed ID: 33120811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia.
    Gacci M; Eardley I; Giuliano F; Hatzichristou D; Kaplan SA; Maggi M; McVary KT; Mirone V; Porst H; Roehrborn CG
    Eur Urol; 2011 Oct; 60(4):809-25. PubMed ID: 21726934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension.
    Drake MJ; Chapple C; Sokol R; Oelke M; Traudtner K; Klaver M; Drogendijk T; Van Kerrebroeck P;
    Eur Urol; 2015 Feb; 67(2):262-70. PubMed ID: 25070148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Silodosin Monotherapy vs Silodosin With Tadalafil Add-on Therapy in Patients With Benign Prostatic Hyperplasia.
    Yoshida T; Kinoshita H; Shimada S; Taguchi M; Matsuda T
    Urology; 2017 Aug; 106():153-159. PubMed ID: 28431996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimuscarinics and α-blockers or α-blockers monotherapy on lower urinary tract symptoms--a meta-analysis.
    Hao N; Tian Y; Liu W; Wazir R; Wang J; Liu L; Wang K; Li H
    Urology; 2014 Mar; 83(3):556-62. PubMed ID: 24361007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tamsulosin and placebo vs tamsulosin and tadalafil in male lower urinary tract symptoms: a double-blinded, randomised controlled trial.
    Nagasubramanian S; John NT; Antonisamy B; Mukha RP; Jeyachandra Berry CS; Kumar S; Devasia A; Kekre NS
    BJU Int; 2020 May; 125(5):718-724. PubMed ID: 32012409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of newer medications for lower urinary tract symptoms attributed to benign prostatic hyperplasia: a systematic review.
    MacDonald R; Brasure M; Dahm P; Olson CM; Nelson VA; Fink HA; Risk MC; Rwabasonga B; Wilt TJ
    Aging Male; 2019 Mar; 22(1):1-11. PubMed ID: 29394114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Combination Comprising Tamsulosin and PDE5-Is, Relative to Monotherapies, in Treating Lower Urinary Tract Symptoms and Erectile Dysfunction Associated With Benign Prostatic Hyperplasia: A Meta-Analysis.
    Sun K; Sun F; Yao H; Zhang D; Wu G; Wang T; Wang J; Wu J
    Am J Mens Health; 2020; 14(6):1557988320980180. PubMed ID: 33342335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic review of combination drug therapy for non-neurogenic male lower urinary tract symptoms.
    Füllhase C; Chapple C; Cornu JN; De Nunzio C; Gratzke C; Kaplan SA; Marberger M; Montorsi F; Novara G; Oelke M; Porst H; Roehrborn C; Stief C; McVary KT
    Eur Urol; 2013 Aug; 64(2):228-43. PubMed ID: 23375241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.